

1 **Same-Day Simultaneous Diagnosis of Bacterial and Fungal Infections in Clinical**
2 **Practice by Nanopore Targeted Sequencing**

3

4 **Running Title:** Pathogens diagnosis by Nanopore Targeted Sequencing

5

6 Ming Wang, MD ^{#1}; Aisi Fu, MS^{#2}; Ben Hu, Ph. D.²; Gaigai Shen, BS²; Ran Liu, MS²;

7 Wanxu Zhao, BS²; Shupeng Jiang, MS¹; Xuan Cai, MD¹; Congrong Li, MD¹; Juan Li, MD¹;

8 Qing Wu, MD¹; Kai Feng, MS¹; Jiashuang Gu, BS³; Jia Chen, MS²; Mingyue Shu, MS²;

9 Binghong Zhang, MD⁴; Zixin Deng, Ph. D.^{2,5,6}; Lilei Yu, MD⁷; Yan Li, MD^{1*}; Tiangang Liu,

10 Ph. D.^{2,6*}

11 ¹ Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060,

12 China

13 ² Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education

14 and Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China

15 ³ Wuhan Dgensee Clinical Laboratory Co., Ltd. Wuhan 430075, China

16 ⁴ Department of Pediatrics, Renmin Hospital of Wuhan University, Wuhan, 430060, China

17 ⁵ State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of

18 Metabolic & Developmental Sciences, and School of Life Sciences and Biotechnology,

19 Shanghai Jiao Tong University, Shanghai, 200030, China

20 ⁶ Hubei Engineering Laboratory for Synthetic Microbiology, Wuhan Institute of

21 Biotechnology, Wuhan, 430075, China

22 ⁷ Department of Internal Medicine, Renmin Hospital of Wuhan University, Wuhan, 430060,

23 China

24 # These authors contributed equally to this work.

25

26 **Corresponding author:**

27 **Prof. Tiangang Liu.** Key Laboratory of Combinatorial Biosynthesis and Drug Discovery,
28 Ministry of Education and Wuhan University School of Pharmaceutical Sciences, Wuhan
29 430071, China. Email: liutg@whu.edu.cn. Tel: +86-27-68755086

30 **Prof. Yan Li.** Department of Clinical Laboratory, Renmin Hospital of Wuhan University,
31 Wuhan, 430060, China Email: yanlitf1120@163.com. Tel: +86-27-88071553

32

33 **Abbreviations:** NTS, nanopore targeted sequencing; ITS1/2, fungal internal transcribed
34 spacers 1 and 2; ATCC, the American Type Culture Collection; MTB, *Mycobacterium*
35 *tuberculosis*; BALF, bronchoalveolar lavage fluid; CFU, colony-forming units; RPM, aligned
36 reads of per million sequence reads; CSF, cerebrospinal fluid; NTM, *Nontuberculous*
37 *mycobacteria*; PPV, positive predicted value; NPV, negative predicted values; OP,
38 opportunistic pathogens; CO, commensal bacteria/fungi

39

40 **Keywords**

41 nanopore sequencing, targeted amplification, pathogens diagnose, bacterial infection, fungal
42 infection

43

44 **Abstract**

45 **BACKGROUND:** As approximately 19% of global deaths are attributable to infectious
46 diseases, early diagnosis of infection is very important to reduce mortality. Traditional
47 infection detection strategies have limited sensitivity, detection range, and turnaround times; a
48 detection technology that can simultaneously detect bacterial and fungal infections within 24
49 h is urgently need in clinical settings.

50

51 **METHODS:** We developed nanopore targeted sequencing (NTS) for same-day simultaneous

52 diagnosis of fungal and bacterial infections. NTS was developed by amplification of 16s
53 rRNA gene (for bacteria), IST1/2 gene (for fungal), and *rpoB* (for *Mycobacterium* spp.) using
54 multiple primers, and sequenced by a real-time nanopore sequencing platform. An in-house
55 bioinformatic analyze pipeline was used to diagnose the infectious pathogens by mapping the
56 sequencing results with the constructed databases.

57

58 **RESULTS:** Comparison of 1312 specimens from 1257 patients using NTS and culture
59 method; NTS detected pathogens in 58.71% of specimens from patients, compared to 22.09%
60 detected using the culture method. NTS showed significantly higher sensitivity than culture
61 methods for many pathogens. Importantly, a turnaround time of <24 h for all specimens, and a
62 pre-report within 6 h in emergency cases was possible in clinical practice. Modification of
63 antibiotic therapy and maintenance of original anti-infection regimens in 51.52% (17/33) and
64 36.36% (12/33) of patients was in accordance with NTS results, and quantitative monitoring
65 of clinical treatment effects was evaluated in four patients by continuous NTS tests.

66

67 **CONCLUSIONS:** Application of NTS in clinically detected pathogens can improve targeted
68 antibiotic treatment and therapeutic monitoring.

69

70 **Introduction**

71 Approximately 19% of global deaths are attributable to infectious diseases, and early
72 empirical treatment may not improve survival rates or other outcomes (1). The low sensitivity
73 or biased detection range of individual techniques results in the combined use of pathogen
74 screening techniques, which will lead to repeated sampling, increased treatment costs, and
75 extended diagnosis time (2-4). Furthermore, the need for rapid pathogen identification, a wide
76 pathogen spectrum (3), limited specimen volumes (5), or even asymptomatic infections (6)

77 should be considered.

78 Enormous progress has been made in the development and deployment of sequencing-based
79 diagnostic methods (4, 7-10). Sequencing-based diagnostic methods have broad detection
80 ranges and high resolution, particularly for fungal pathogens. However, unbiased
81 metagenomic methods typically require deep sequencing and extensive bioinformatics
82 processing to account for host genome dominance, resulting in low-throughput, high costs,
83 long turnaround times, and low sensitivity (4, 11). Targeted sequence detection requires less
84 sequencing data and bioinformatics resource, which in theory, can reduce the cost and
85 turnaround time, therefore suitable for clinical applications. However, due to the short-read
86 lengths of previous sequencing platforms, its discrimination of pathogens is limited by
87 incompletely sequenced marker genes, such as the V4-5 region of 16s rRNA gene. The
88 detection range was also restricted to only bacteria or fungi in a single test due to their
89 different sized marker genes which cannot be constructed in same sequencing library (8, 12).

90 DNA is sequenced by massively parallel sequencing platforms by detecting optical or
91 chemical signals. This method accumulates systematic errors generated by sequencing as the
92 sequencing length increases, limiting the length of sequencing reads (13, 14). Illumina's (the
93 most widely used massive parallel sequencing platform) sequencing by synthesis approach
94 requires multiple sequencing cycles, and each cycle takes several minutes to analyze one base
95 of each DNA fragment. Hence, the sequencing process usually takes 0.5 to 3 days according
96 to the read length and data output requirement. More importantly, the sequencing data cannot
97 be used for following analysis until the entire sequencing process is completed. Nanopore
98 sequencing platform's approach directly detects changes in the generated current when DNA /
99 RNA molecules pass through a nanopore protein at approximately 300 bp/s, which now
100 achieving >95% raw read accuracy (15). This electrical signal can be recorded in real-time

101 and used for subsequent sequence analysis immediately (16). In addition, the nanopore
102 protein does not selectively sequence DNA / RNA with specific lengths. DNA / RNA of
103 different lengths can pass through the nanopore protein completely, and the length of each
104 sequencing data is equal to that of the length of the DNA / RNA (17). Therefore, unlike
105 previous sequencing platforms, the length of nucleic acids in the same sequencing library is
106 not required to be of a specific range, such as 280-320 bp; all nucleic acids with different
107 length can be pooled together and sequenced from end to end in a nanopore sequencing
108 library (18, 19).

109 Real-time data output, end to end sequencing and small size make nanopore sequencing
110 promising for clinical applications. Previous studies focused on bacterial respiratory infection
111 using nanopore metagenome sequencing (20-22), however the clinical application was
112 impeded by relative high costs and extensive bioinformatics processing. Nanopore targeted
113 sequencing (NTS), which amplified marker genes and used nanopore sequencing platform to
114 sequence the amplified marker genes, were developed for investigation of bacterial or fungal
115 infection. However, previous NTS was only based on a single marker gene, such as the 16s
116 rRNA gene targeted sequencing that has been reported to identify bacterial infection in
117 individual clinical case reports (23, 24), and fungal ribosomal operon (18S-ITS1-5.8S-ITS2-
118 28S) has been used to detect the fungal community associated with external otitis in dogs (25).
119 Simultaneous broad-spectrum detections of bacteria and fungi, and high-sensitivity detection
120 of critical clinical pathogens in clinical samples by a single test based on NTS have not been
121 developed. In addition, the performance of the NTS method with a large cohort and
122 systematic comparisons with classic culture methods have not been examined. Furthermore,
123 the turnaround time in clinical practice and clinical management applications are unknown.

124 Here, we developed a test based on NTS for the broad-spectrum screening of both bacterial
125 and fungal pathogens in various clinical specimen types. The diagnostic accuracy and

126 turnaround time of NTS were investigated by comparison with the culture method for 1312
127 clinical specimens from 1257 patients.

128

129 **Materials and Methods**

130 SPECIMENS AND CLINICAL ELECTRONIC RECORD

131 The study population consisted of 1312 specimens from 1257 patients at Renmin Hospital of
132 Wuhan University, China, whose specimens were sent for pathogen testing between
133 November 2018 and November 2019. Parallel testing by routine culture and NTS was
134 performed. Adequate material was submitted for culture, and surplus material was processed
135 by NTS. All specimens (n = 1312) were used to assess the NTS and culture results. The
136 clinical records of each patient were retrieved and 1005 patients were diagnosed or suspected
137 with infection by clinicians according to clinical symptoms and/or positive results of other
138 clinical tests. These patients were used to evaluate the diagnostic yield and sensitivity of NTS.
139 Patient clinical diagnosis and demographic characteristics were obtained from electronic
140 medical records (26). The study was approved by the Ethics Committee of Renmin Hospital
141 of Wuhan University (WDRY2019-K056).

142 NTS

143 All primers used in this study are listed in [Table S1](#), the DNA extraction method of specimen
144 was described in [supporting method](#). Amplification of the 16s rRNA gene and *rpoB* was
145 performed in a 20 μ L reaction system with 8 μ L extracted DNA, 2 μ L barcoded primer (10
146 μ M), and 10 μ L 2 \times KOD OneTM PCR Master Mix (TOYOBO) using the following
147 procedure: 1 cycle at 98 $^{\circ}$ C for 3 min and 35 cycles at 98 $^{\circ}$ C for 10 s, 55 $^{\circ}$ C for 5 s, and 68 $^{\circ}$ C
148 for 10 s, followed by a final elongation step at 68 $^{\circ}$ C for 5 min. ITS1/2 (fungal internal

149 transcribed spacers 1 and 2, abbreviated as ITS1/2) was first amplified using the same
150 reaction system and PCR procedure using the primer mix without barcode and the PCR
151 product was purified with 0.8× AMPure beads (Beckman Coulter) and eluted in 10 µL Tris-
152 EDTA (TE) buffer. Then, 5 µL eluate was used for barcoding PCR with 5 µL barcoded
153 ITS1/2 primer set (10 µM) and 10 µL 2× Phusion U Multiplex PCR Master Mix using the
154 following procedure: 1 cycle at 98°C for 3 min and 10 cycles at 98°C for 10 s, 55°C for 5 s,
155 and 68°C for 5 s, followed by a final elongation step at 68°C for 5 min. The barcoded
156 products of the 16s rRNA gene, ITS1/2 and *rpoB* amplification from the same samples were
157 pooled according to mass ratio of 10:3:1. The pooled products from the different samples
158 were mixed equally and used to construct sequencing libraries using the 1D Ligation Kit
159 (SQK-LSK109; Oxford Nanopore). The library was sequenced using Oxford Nanopore
160 MinION or GridION. TE buffer was assayed in each batch as a negative control. The
161 bioinformatic analysis was described in the supplement methods section, several
162 modifications were made following previous studies and samples were tested positive for
163 bacteria or fungi if they met any of the established thresholds ([Supporting method](#)). Detected
164 microorganisms were described as critical pathogens, opportunistic pathogens, or typically
165 nonpathogenic commensal microbes according to published literature and clinical guidelines
166 (27) ([Table S2](#)).

167 MOCK COMMUNITY

168 All 50 clinical strains used to evaluate performance were isolated from clinical specimens in
169 the laboratory or purchased from the American Type Culture Collection (ATCC) (Manassas,
170 VA, USA). Six strains were selected to construct a mock community ([Table S3](#)) and blood
171 samples were collected from healthy volunteers with no symptoms of infection in physical
172 examination. The concentration of each strain was determined by calibration curves from
173 cultures.

174 STATISTICAL ANALYSIS

175 The sensitivity, specificity, positive predictive value (PPV), and negative predictive value
176 (NPV) were calculated as previously described by comparing the NTS results with composite
177 final clinical diagnosis (28). A P-value < 0.05 was considered significant. Proportional
178 outcomes were compared using the χ^2 test or Fisher's exact test. Continuous variables were
179 compared using the Student's *t*-test or Wilcoxon signed-rank test. Data analyses were
180 performed using SPSS 22.0.

181

182 **Results**

183 DESIGN OF NTS FOR SAME-DAY SIMULTANEOUS DIAGNOSIS OF BACTERIAL 184 AND FUNGAL INFECTIONS

185 Full-length bacterial 16s rRNA gene and fungal ITS1/2 gene were selected as universal
186 marker genes for identification of bacteria and fungi, respectively. For specific markers, as
187 *Mycobacterium tuberculosis* (MTB) was the most concerned clinical critical pathogen, we
188 chose *rpoB* for *Mycobacterium* spp. (29) as the target. The design of NTS primers (Table S1)
189 and the sequencing library preparation were described in the [supporting result](#). For sequencing,
190 we chose a nanopore platform that could sequence long nucleic acid fragments and
191 simultaneously analyze the data-output in real-time. This allowed immediate detection of
192 bacterial and fungal infection by periodical analysis of output sequences using our in-house
193 bioinformatic pipeline ([supporting methods](#)). In summary, a NTS detection that targeted the
194 amplification of bacterial and fungal marker genes and that is able to execute nanopore
195 sequencing to identify the pathogens was developed ([Fig. 1](#)).

196

197 PERFORMANCE OF NTS BASED ON STANDARD STRAINS AND MOCK
198 COMMUNITIES

199 To verify the identification accuracy, NTS was tested by individual analyses of 50 common
200 clinical strains isolated from clinical specimens in the laboratory or purchased from ATCC. In
201 total, 100% and 92% of the tested isolates were identified correctly at the genus and species
202 level, respectively (Table S4). Considering clinical samples, such as sputum, that usually
203 contain high abundance of commensal microbes and that the pathogens may have relatively
204 lower abundance, in order to investigate the sensitivity and sequencing data required for
205 detection the low-abundance microbes, a mock community (three bacteria and three fungi)
206 was constructed to simulate a complex clinical sample and the concentration of each strain
207 was determined by calibration curves from cultures (Table S3). Considering that different
208 levels of background human DNA could potentially affect sensitivity, the performance of
209 NTS was tested using healthy human blood spiked with varied concentrations of the mock
210 community. NTS detected each species at all six pathogen densities, and the least abundant
211 fungi and bacteria, with 25 colony-forming units (CFU) in a community of 1000 CFU, were
212 consistently detected in 12 repeats (Fig. 2A, B). Therefore, the limit of detection was
213 determined to be 25 CFU in 12/12 positive replicates (Table S5).

214 To determine a proper sequencing time (corresponding to sequencing data) that is required for
215 confident detection of different amounts of microbes in community, a sequencing library
216 contained that 48 samples was sequenced on a chip for 12 h. The most abundant bacteria or
217 fungi, accounting for 30% of the mock community, were detected in all 12 repeats using total
218 400,000 sequencing reads, which required approximately 30 min. Meanwhile the least
219 abundant bacteria or fungi, accounting for 5% of the mock community, were identified using
220 total 2,000,000 reads, which required approximately 4 h (Fig. 2C, D). This indicated that 4 h
221 sequencing was enough for detection of all pathogens and that a sequencing library with

222 fewer samples could reduce the sequencing time. Considering the diversity of clinical samples,
223 in which pathogens may account for >30% or <5% of the microbial community, the pathogen
224 detection time can be achieved <30-minute or require > 4 h of sequencing time.

225

226 COMPARISON OF NTS AND CULTURE METHOD IN CLINICAL PRACTICE

227 Upon verification of the performance of NTS using the mock community, 1312 clinical
228 specimens from 1257 patients were parallelly analyzed by NTS and culture, including 301
229 and 1011 specimens from sterile (low commensal microbes background) and non-sterile
230 settings (high commensal microbes background), respectively.

231 Using the culture-based results as a reference, among 289 culture-positive cases, NTS
232 detected pathogens in 97.58% cases ($n = 282/289$), including identical findings to culture
233 results in 52.94% cases ($n = 153/289$), detection of additional potential pathogens other than
234 the culture results in 30.44% of cases ($n = 88/289$), different species of same genus detected
235 between NTS and culture (6.92%, $n = 20/289$) and different pathogens detected between two
236 methods (7.27%, $n = 21/289$) (Fig. 3A). Considering the different growth rates of bacteria and
237 fungi, 84 of the 88 cases of additional pathogens detected by NTS were diagnosed as bacterial
238 or fungal infections only by culture methods, in which additional critical pathogens ($n = 2$),
239 additional opportunistic fungi or bacteria ($n = 67$), and potential coinfection with
240 opportunistic fungi and bacteria ($n = 19$) were detected (Fig. 3A). The NPV of NTS (culture
241 as reference) was 98.88%, which indicated that NTS was able to detect most of the pathogens
242 identified by culture (Table 1). The pathogens detected by culture methods were missed by
243 NTS in 2.42% cases ($n = 7/289$), in which high background of commensal microbes may
244 impact the detection of pathogen with low abundance.

245 Of the 1023 specimens identified as culture-negative, potential pathogens were detected in
246 39.78% cases (n = 407/1023) by NTS, especially including 63 critical pathogens (Fig. 3A). In
247 order to evaluate the accuracy of the NTS results of these cases, GeneXpert (a Food and Drug
248 Administration-approved assay based on specific PCR of *rpoB* in MTB) analysis was
249 conducted in 27/34 MTB-positive patients determined by NTS, and 100% concordance was
250 observed; the other 7 patients were confirmed by acid-fast staining (n = 2) or transferred to a
251 specialized hospital according to the clinical symptoms without further confirmation (n = 5)
252 (Table S6).

253 According to the clinical diagnosis record around the time of the parallel NTS and culture test,
254 1005/1257 patients were diagnosed or suspected as infection by clinicians according to the
255 clinical symptoms and/or positive results of other clinical tests. However, culture only
256 reported 289 positive cases, which indicated that several pathogens could have been missed
257 and could not to be a reference for comprehensive assess of NTS. Thus, clinical diagnosis was
258 used to evaluate the performance of NTS in infection diagnosis and practicability in clinical
259 application. The sensitivity of NTS (diagnose as reference) were 58.7% (n = 590/1005),
260 which was >36% higher than that for culture-based methods (22.1%, n = 222/1005, $P < 0.01$),
261 and 52 more potential coinfections with bacteria and fungi were detected by NTS (Table 1).
262 For slow-growing, fastidious pathogens, NTS exhibited a significantly higher positive
263 detection rate compared to that of culture methods, particularly for MTB (34 vs. 4),
264 *Aspergillus* (80 vs. 20), *Pneumocystis jirovecii* (20 vs. 0), and *Nocardia* (9 vs. 3) (Table 1).
265 Moreover, considering the antibiotic pre-exposure in nearly all patients from the Departments
266 of Respiration and Neurology, no colonies, including fast-growing oral flora and colonizers,
267 grew after a 72-h incubation period in 44/401 and 55/62 specimens, among which NTS
268 showed 40.9% (n = 18/44) and 21.0% (n = 12/55) positive results. In those NTS-positive
269 samples, 11/18 (61.1%) and 10/12 (83.3%) were culturable pathogens, such as *Streptococcus*

270 *aureus* (Table S7).

271 Specimen volume, types of pathogens, abundance of colonizing microorganisms, and
272 concentration of human DNA backgrounds in different clinical specimens existed to a large
273 diversity. To assess the impact of different types of specimens on the efficiency of NTS
274 testing, we evaluated the sensitivity of NTS in different specimens. The positive rate of NTS
275 was higher than that of culture methods, particularly in the aqueous humor, which usually has
276 limited specimen volume (60.0% vs. 10.0%, $P < 0.05$), and bronchoalveolar lavage fluid
277 (BALF), which usually contains high abundance of commensal microbes (56.4% vs. 14.8%, P
278 < 0.05), except for superficial secretions ($P = 0.08$) in which the main pathogens were fast-
279 growing bacteria, such as *Streptococcus aureus* (Fig. 3B). These results indicated that
280 detection sensitivity of NTS was less impacted by the type of specimen and that NTS was
281 suitable for the infection detection of various specimens.

282 For all specimens, considering the complexity of clinical samples and more sequencing data
283 may improve sensitivity, the default total sequencing time was defined as 8 h; the time from
284 sample collection to the generation of the pathogen report was within 24 h for NTS ($n = 1312$),
285 which was significantly shorter than the estimated median time of 72 h for culture methods (P
286 < 0.001) (Fig. 4). Notably, real-time information was generated during sequencing, and a pre-
287 report can be obtained if the data meet the positive criteria, further reducing the turnaround
288 time. Briefly, in many emergency cases, 10 min sequencing data was sufficient to identify the
289 pathogens and targeted antibiotics can be administrated by clinicians on the same day of
290 detection without waiting for the completion of an 8 h sequencing.

291 EFFECT OF NTS ON ANTIBIOTIC MANAGEMENT

292 To assess the impact of pathogen detection by NTS on antibiotic management, we
293 investigated the patients' electronic records. Empirical antimicrobial agents were initiated

294 before NTS in 93.9% (31/33) of NTS-positive samples in the Department of Respiratory ICU.
295 Based on the NTS results, 51.52% (17/33) of patients were switched to targeted antibiotics (n
296 = 7) or different antibiotics covering the same antibacterial spectrum (n = 10). NTS results did
297 not trigger modification of antibiotic therapy in 42.42% (14/33) of patients; among these
298 patients, 85.71% (12/14) maintained the original anti-infection regimen, which already
299 covered the pathogen detected by NTS, and 14.29% (2/14) were discharged from hospital
300 without subsequent therapy (Table S8). Four patients were evaluated by continuous NTS
301 assay during the treatment process. In four cases, the pathogens detected in the first NTS
302 assay and triggering antibiotic modification were eliminated according to the results of the
303 second NTS assay, resulting in the suspension or de-escalation of targeted antibiotics. In one
304 case, other pathogen were detected in the second NTS, which may have been transient
305 colonizers with the potential to induce a nosocomial infection (Table 2).

306

307 **Discussion**

308 We developed and examined the performance and clinical impact of targeted full-length
309 amplicon sequencing in clinical practice, in a setting where most patients have negative
310 culture results (8). NTS increased the sensitivity of pathogen detection for patients with
311 diagnosed or suspected infection and detected more causative pathogens in patients with a risk
312 of infection. These findings are consistent with those of previous sequencing-based studies (6,
313 8, 30, 31). Compared to culture methods, the detection rate by NTS was higher for nearly all
314 specimen types, particularly in the cerebrospinal fluid (CSF) and aqueous humor. Moreover,
315 slow-growing, uncultivable pathogens were detected in a single NTS test, particularly fungi
316 and MTB (32). For infections induced by culturable bacteria, NTS was less impacted by pre-
317 antibiotic exposure and more effectively detected coinfections. Potential pathogens were
318 detected in specimens with no clone growth in culture. Continuous NTS helped clinicians

319 determine effective treatments, suspend, or de-escalate the use of targeted drugs, and monitor
320 the risk of secondary or nosocomial infections.

321 By NTS, a turnaround time of <24 h can be achieved for all specimens. Given its high NPV
322 using culture results for reference, a negative result or non-bacterial etiology can lead to de-
323 escalation or even the discontinuation of antimicrobial therapy (33). Moreover, a 6-h
324 diagnostic pre-report can be issued if diagnostic thresholds are met. We encountered
325 emergency cases for which this pre-report substantially improved the diagnosis and care. We
326 identified *Nocardia farcinica*, which is rare in China, in a patient with an emergency
327 intracranial infection, and extremely fast-growing pathogens in the tissue of a patient with
328 Paget's disease. In addition, NTS detection of fungi and rare coinfections of fungi with
329 symbiotic bacteria, often neglected by routine clinical diagnosis, is possible.

330 Our results clearly support the combination of targeted amplification and nanopore
331 sequencing; however, amplification may alter the flora structure, affecting the detection of
332 pathogens with ultralow abundance. A total of 80% of NTS false-negative samples were
333 derived from the respiratory tract, suggesting that the extremely high proportion of
334 commensal colonizers by improper sample procurement impacted the sensitivity of NTS.
335 NTS amplification requires adjustment depending on the specimen type. Importantly, many
336 potentially pathogenic bacteria, such as *Pseudomonas* and *Streptococcus*, are ubiquitous (27),
337 and their abundance must be contextualized by cohort-specific norms.

338 This study had several limitations. First, it was conducted at a single central hospital, and the
339 number of specimens varied substantially among departments. Further studies at hospitals
340 with different patient populations and medical practices are needed. Second, unmeasured
341 factors may have influenced decision-making. In addition, we cannot measure the impact of
342 NTS on patient outcomes beyond antibiotic selection. Finally, given the retrospective nature
343 of the study, all available tests were not performed on all samples, and we did not
344 systematically compare NTS results to those of other molecular diagnostic methods. Future

345 studies should focus on the impact of NTS on patient-centered outcomes (i.e., length of stay
346 and mortality), antibiotic stewardship, and cost compared to a wider range of methods.

347 In conclusion, the NTS approach developed in this study enabled simultaneous detection and
348 same-day reporting of a myriad of bacteria and fungi in specimens with practical operability
349 in clinical settings. This approach fills the gap between highly targeted PCR-based diagnostic
350 methods and resource-intensive sequencing-based metagenomics methods. The equipment
351 required for NTS testing is small and portable; therefore, NTS can be directly performed in
352 various hospitals or clinics, without sending specimens to large sequencing institutions or
353 third parties detection institutions. NTS is recommended for monitoring severe patients during
354 treatment because of its accuracy, comprehensiveness, and rapidity.

355

356 **Conflicts of interest**

357 Wuhan Dgensee Clinical Laboratory Co., Ltd applied patents based on this novel technology.


358

359 **Reference**

- 360 1. Yang CC, Sy CL, Huang YC, Shie SS, Shu JC, Hsieh PH, et al. Risk factors of treatment
361 failure and 30-day mortality in patients with bacteremia due to mrsa with reduced
362 vancomycin susceptibility. *Sci Rep* 2018;8:7868.
- 363 2. Laxminarayan R, Matsoso P, Pant S, Brower C, Rottingen JA, Klugman K, Davies S.
364 Access to effective antimicrobials: A worldwide challenge. *Lancet* 2016;387:168-75.
- 365 3. Wilson MR, O'Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, et al.
366 Chronic meningitis investigated via metagenomic next-generation sequencing. *JAMA*
367 *Neurol* 2018;75:947-55.
- 368 4. Simner PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic
369 next-generation sequencing as a diagnostic tool for infectious diseases. *Clin Infect Dis*
370 2018;66:778-88.
- 371 5. Ivy MI, Thoendel MJ, Jeraldo PR, Greenwood-Quaintance KE, Hanssen AD, Abdel MP, et
372 al. Direct detection and identification of prosthetic joint infection pathogens in
373 synovial fluid by metagenomic shotgun sequencing. *J Clin Microbiol* 2018;56.
- 374 6. Langelier C, Kalantar KL, Moazed F, Wilson MR, Crawford ED, Deiss T, et al. Integrating
375 host response and unbiased microbe detection for lower respiratory tract infection
376 diagnosis in critically ill adults. *P Natl Acad Sci USA* 2018;115:E12353-E62.
- 377 7. Langelier C, Zinter MS, Kalantar K, Yanik GA, Christenson S, O'Donovan B, et al.
378 Metagenomic sequencing detects respiratory pathogens in hematopoietic cellular
379 transplant patients. *Am J Respir Crit Care Med* 2018;197:524-8.


- 380 8. Basein T, Gardiner BJ, Andujar Vazquez GM, Joel Chandranesan AS, Rabson AR, Doron
381 S, Snyderman DR. Microbial identification using DNA target amplification and
382 sequencing: Clinical utility and impact on patient management. *Open Forum Infect Di*
383 *2018;5:ofy257*.
- 384 9. Clarke EL, Lauder AP, Hofstaedter CE, Hwang Y, Fitzgerald AS, Imai I, et al. Microbial
385 lineages in sarcoidosis. A metagenomic analysis tailored for low-microbial content
386 samples. *Am J Respir Crit Care Med* 2018;197:225-34.
- 387 10. Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, et
388 al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa:
389 A prospective metagenomic study. *Clin Infect Dis* 2017;65:282-91.
- 390 11. Simner PJ, Miller HB, Breitwieser FP, Pinilla Monsalve G, Pardo CA, Salzberg SL, et al.
391 Development and optimization of metagenomic next-generation sequencing methods
392 for cerebrospinal fluid diagnostics. *J Clin Microbiol* 2018;56.
- 393 12. Stefan CP, Hall AT, Minogue TD. Detection of 16s rna and kpc genes from complex
394 matrix utilizing a molecular inversion probe assay for next-generation sequencing. *Sci*
395 *Rep* 2018;8:2028.
- 396 13. Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, Waterston
397 RH. DNA sequencing at 40: Past, present and future. *Nature* 2017;550:345-53.
- 398 14. Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation
399 sequencing technologies. *Nat Rev Genet* 2016;17:333-51.
- 400 15. New research algorithms yield accuracy gains for nanopore sequencing.
401 [https://nanoporetech.com/about-us/news/new-research-algorithms-yield-accuracy-](https://nanoporetech.com/about-us/news/new-research-algorithms-yield-accuracy-gains-nanopore-sequencing)
402 [gains-nanopore-sequencing](https://nanoporetech.com/about-us/news/new-research-algorithms-yield-accuracy-gains-nanopore-sequencing)
- 403 16. Deamer D, Akeson M, Branton D. Three decades of nanopore sequencing. *Nat Biotechnol*
404 *2016;34:518-24*.
- 405 17. Petersen LM, Martin IW, Moschetti WE, Kershaw CM, Tsongalis GJ. Third-generation
406 sequencing in the clinical laboratory: Exploring the advantages and challenges of
407 nanopore sequencing. *J Clin Microbiol* 2019;58.
- 408 18. Kono N, Arakawa K. Nanopore sequencing: Review of potential applications in functional
409 genomics. *Dev Growth Differ* 2019;61:316-26.
- 410 19. Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, et al. The potential
411 and challenges of nanopore sequencing. *Nat Biotechnol* 2008;26:1146-53.
- 412 20. Votintseva AA, Bradley P, Pankhurst L, Del Ojo Elias C, Loose M, Nilgiriwala K, et al.
413 Same-day diagnostic and surveillance data for tuberculosis via whole-genome
414 sequencing of direct respiratory samples. *J Clin Microbiol* 2017;55:1285-98.
- 415 21. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, et al. Nanopore
416 metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection.
417 *Nature biotechnol* 2019;37:783-92.
- 418 22. Yang L, Haidar G, Zia H, Nettles R, Qin S, Wang X, et al. Metagenomic identification of
419 severe pneumonia pathogens in mechanically-ventilated patients: A feasibility and
420 clinical validity study. *Respir Res* 2019;20:265.
- 421 23. Moon J, Jang Y, Kim N, Park WB, Park KI, Lee ST, et al. Diagnosis of haemophilus
422 influenzae pneumonia by nanopore 16s amplicon sequencing of sputum. *Emerging*
423 *Infect Dis* 2018;24:1944-6.
- 424 24. Moon J, Kim N, Lee HS, Shin HR, Lee ST, Jung KH, et al. *Campylobacter fetus*
425 meningitis confirmed by a 16s rna gene analysis using the minion nanopore
426 sequencer, south korea, 2016. *Emerg Microbes Infect* 2017;6:e94.
- 427 25. D'Andreano S, Cuscó A, Francino O. Rapid and real-time identification of fungi up to the
428 species level with long amplicon nanopore sequencing from clinical samples. *bioRxiv*
429 *2020:2020.02.06.936708*.

- 430 26. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN,
431 Huffnagle GB. Analysis of culture-dependent versus culture-independent techniques
432 for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. *J Clin*
433 *Microbiol* 2014;52:3605-13.
- 434 27. Zinter MS, Dvorak CC, Mayday MY, Iwanaga K, Ly NP, McGarry ME, et al. Pulmonary
435 metagenomic sequencing suggests missed infections in immunocompromised children.
436 *Clin Infect Dis* 2018.
- 437 28. Miao Q, Ma Y, Wang Q, Pan J, Zhang Y, Jin W, et al. Microbiological diagnostic
438 performance of metagenomic next-generation sequencing when applied to clinical
439 practice. *Clin Infect Dis* 2018;67:S231-S40.
- 440 29. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, et al. Identification of
441 mycobacterial species by comparative sequence analysis of the rna polymerase gene
442 (rpoB). *J Clin Microbiol* 1999;37:1714-20.
- 443 30. Gomez CA, Budvytiene I, Zemek AJ, Banaei N. Performance of targeted fungal
444 sequencing for culture-independent diagnosis of invasive fungal disease. *Clin Infect*
445 *Dis* 2017;65:2035-41.
- 446 31. Cherkaoui A, Emonet S, Ceroni D, Candolfi B, Hibbs J, Francois P, Schrenzel J.
447 Development and validation of a modified broad-range 16s rDNA PCR for diagnostic
448 purposes in clinical microbiology. *J Microbiol Meth* 2009;79:227-31.
- 449 32. Rampini SK, Bloemberg GV, Keller PM, Buchler AC, Dollenmaier G, Speck RF, Bottger
450 EC. Broad-range 16s rRNA gene polymerase chain reaction for diagnosis of culture-
451 negative bacterial infections. *Clin Infect Dis* 2011;53:1245-51.
- 452 33. Parize P, Muth E, Richaud C, Gratigny M, Pilimis B, Lamamy A, et al. Untargeted next-
453 generation sequencing-based first-line diagnosis of infection in immunocompromised
454 adults: A multicentre, blinded, prospective study. *Clin Microbiol Infect* 2017;23:574
455 e1- e6.
456



457

458 **Fig. 1.** Design of NTS for simultaneous detection of bacterial and fungal infection. Three marker gene databases, corresponding to 16s rRNA,
 459 ITS1/2, and *rpoB*, were constructed from the sequences from the NCBI database. The results of multiplex sequence alignment of each database was
 460 used to analyze the conservative region and degeneration of each marker gene base. The blue primers were used in previous studies and selected as
 461 “start primers” for the design of other “additional primers” which is labeled by other colors. The red vertical bar on the primer indicates degenerate
 462 base. The “start primers” and “additional primers” for each marker gene was mixed at the molar ratio of 3:1. The mixed primers were then used to
 463 amplify the marker gene, individually. The PCR products of the 16s rRNA, ITS1/2, and *rpoB* from the same sample were then pooled at a mass
 464 ratio of 10:3:1. This pooled product was used for library preparation, nanopore sequencing and bioinformatic analysis.




465

466 **Fig. 2.** Proficiency test of NTS with a mock community. Detection of the least abundant
467 bacteria (A) and fungi (B) in the mock community. *Moraxella catarrhalis* and *Candida*
468 *tropicalis* each accounted for 5% of the mock community. Three different densities from 25
469 to 150 CFU/mL were tested with 12 repeats. Each spot represents a repeat detection. (C)
470 Comparison of the RPM of each strain in the mock community in a saline background with
471 that in human blood. The correlation between the detection of bacteria (C) and fungi (D) with
472 sequencing data used for the analysis. Dashed line indicates the positive threshold between
473 the sample and control used as the limit of detection for pathogens in this study.
474 Abbreviations: NTS, nanopore targeted sequencing; CFU, colony-forming units; RPM,
475 aligned reads of per million sequence reads.

476


477



478
 479 **Fig. 3.** Comparison of NTS and culture method in real clinical practice. (A) Evaluation of
 480 concordance between NTS and culture results. Detected microbes were defined as critical or
 481 opportunistic bacteria or fungi according to previous studies and clinical guidelines. (B)
 482 Positive rates of NTS for each kind of specimen compared to that of culture results using the
 483 clinical diagnosis of each patient as reference. Abbreviations: NTS, nanopore targeted
 484 sequencing; BALF, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid.

485

Timeline of NTS in real clinical practice



486

487

488 **Fig. 4.** Schematic illustration of the total duration of NTS in clinical practice, including
489 pretreatment, DNA extraction, targeted amplification and library construction, sequencing,
490 bioinformatic analysis, and generation of the real-time report.

491

492 **Table 1. Diagnostic Performance of NTS and Culture**

| | Culture | NTS | P value |
|---|---|----------------------|----------------|
| Diagnostic performance according to clinical diagnosis | | | |
| Sensitivity refer to clinical diagnosis | 22.09%, 222/1005 | 58.71%, 590/1005 | < .01 |
| Diagnostic performance according to culture diagnosis | | | |
| Sensitivity refer to culture | - | 97.57%, (282+7) | 282/ - |
| Specificity refer to culture | - | 60.21%, (616+407) | 616/ - |
| PPV refer to culture | - | 40.92%, (282+407) | 282/ - |
| NPV refer to culture | - | 98.87%, (616+7) | 616/ - |
| Detection of different pathogens | | | |
| Coinfection of bacteria and fungi | 8 | 60 | < .01 |
| MTB | 4, 4/4 detected by NTS | 34 | < .01 |
| <i>Cryptococcus</i> | 2, 2/2 detected by NTS | 9 | ns |
| <i>Streptococcus aureus</i> | 28, 28/28 detected by NTS | 58 | < .01 |
| <i>Escherichia coli</i> | 33, 31/33 detected by NTS | 68 | < .01 |
| <i>Klebsiella pneumoniae</i> | 22, 20/22 detected by NTS | 44 | < .01 |
| <i>Enterococcus</i> | 31, 23/31 identical and 7/31 with different species detected by NTS | 91 | < .05 |
| <i>Acinetobacter baumannii</i> | 54, 51/54 detected by NTS | 91 | < .05 |
| <i>Haemophilus influenzae</i> | 3, 3/3 detected by NTS | 53 | < .01 |
| <i>Candida</i> | 27, 27/27 detected by NTS | 160 | < .01 |
| <i>Nocardia</i> | 3, 3/3 detected by NTS | 9 | < .01 |
| <i>Aspergillus</i> | 20, 15/20 detected by NTS | 80 | < .01 |
| <i>Pneumocystis jirovecii</i> | 0 | 20 | < .01 |
| <i>Bordetella</i> | 0 | 3 | < .01 |
| <i>Legionella</i> | 0 | 2 | < .01 |
| <i>Tropheryma whipplei</i> | 0 | 5 | < .01 |
| NTM | 0 | 3 | < .01 |
| <i>Mycoplasma pneumoniae</i> | 0 | 59 | < .01 |
| <i>Ureaplasma</i> | 0 | 10 | < .01 |

| | | | | |
|--|------------------------------|---|----|-------|
| | <i>Gardnerella vaginalis</i> | 0 | 20 | < .01 |
|--|------------------------------|---|----|-------|

493

494 Abbreviation: NTS, nanopore targeted sequencing; MTB, *Mycobacterium tuberculosis*; NTM,

495 *Nontuberculous mycobacteria*; PPV, positive predicted value; NPV, negative predicted values.

496 **Table 2. Continuous NTS assay during the treatment process**

| Patient number | Test times | Culture Result | NTS Result | Clinical Diagnosis | Antibiotics and Therapeutic Effect |
|----------------|------------|------------------------------|--|--------------------------------|--|
| PT.35 | 1st assay | Negative | <i>Pneumocystis jirovecii</i> CO: <i>Staphylococcus epidermidis</i> | Severe pneumonia | 1. (Antibiotics before 1 st NTS) cefoperazone, ganciclovir, moxifloxacin, and then imipenem, voriconazole, sulfonamide 2. (Therapeutic effect before 1 st NTS) the patient's condition worsened |
| | 2nd assay | Negative | CO: <i>Staphylococcus haemolyticus</i> | | 3. (Antibiotics after 1 st NTS) sulfonamide 4. (Therapeutic effect after 2 nd NTS) Discharged |
| PT.26 | 1st assay | <i>Klebsiella pneumoniae</i> | OP: <i>Klebsiella pneumoniae</i> CO: <i>Streptococcus mitis</i> | Neonatal respiratory infection | 1. (Antibiotics before 1 st NTS) imipenem, linezolid, cefotiam, and cefoperazone 2. (Therapeutic effect before 1 st NTS) The index of infection was significantly increased |
| | 2nd assay | Negative | CO: <i>Enterococcus faecalis</i> | | 3. (Antibiotics after 1 st NTS) cefoperazone discontinuation and meropenem treatment 4. (Therapeutic effect after 2 nd NTS) Discharged |
| PT.48 | 1st assay | <i>Aspergillus</i> | OP: <i>Aspergillus</i> | Severe pneumonia | 1. (Antibiotics before 1 st NTS) imipenem, voriconazole 2. (Antibiotics after 1 st NTS) voriconazole was discontinued and caspofungin was administrated |
| | 2nd assay | Negative | Negative | | 3. (Therapeutic effect after 2 nd NTS) The patient's lung infection was better than before according to CT |

| | | | | | |
|-------|-----------|--------------------------------|---|------------------------------|--|
| PT.11 | 1st assay | Negative | OP: <i>Streptococcus pneumoniae</i> CO: <i>Neisseria flavus</i> , <i>Gemella sanguinis</i> | Community pneumonia acquired | 1. (Antibiotics before 1 st NTS) routine anti-infective treatment |
| | 2nd assay | <i>Acinetobacter baumannii</i> | OP: <i>Acinetobacter baumannii</i> Candida albicans | | 2. (Antibiotics after 1 st NTS) Considering pneumonia of <i>streptococcus pneumoniae</i> and the current anti-infective treatment regimen was continued 3. (Therapeutic effect After 1 st NTS) Indexs of infection decreased, but there was still a high fever at night. 4. (Antibiotics after 2 nd NTS) Imipenem cisastatin and micafungin 5. (Therapeutic effect After 2 nd NTS) Discharged |

497

498

499

500

Abbreviation : NTS, nanopore targeted sequencing; OP, opportunistic pathogens; CO, commensal bacteria/fungi